Mirae Asset Global ETFs Holdings
ABUS icon

Mirae Asset Global ETFs Holdings’s Arbutus Biopharma ABUS Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$411K Buy
85,939
+6,473
+8% +$28.4K ﹤0.01% 2101
2026
Q1 		$356K Buy
79,466
+2,307
+3% +$10.1K ﹤0.01% 2063
2025
Q4 		$370K Buy
77,159
+3,353
+5% +$15.1K ﹤0.01% 2039
2025
Q3 		$335K Sell
73,806
-13,543
-16% -$49.7K ﹤0.01% 2055
2025
Q2 		$270K Sell
87,349
-3,820
-4% -$12.7K ﹤0.01% 2122
2025
Q1 		$318K Buy
91,169
+1,772
+2% +$5.91K ﹤0.01% 2085
2024
Q4 		$292K Buy
89,397
+8,308
+10% +$30.6K ﹤0.01% 2189
2024
Q3 		$312K Buy
81,089
+16,009
+25% +$61.4K ﹤0.01% 2145
2024
Q2 		$201K Buy
+65,080
New +$195K ﹤0.01% 2249

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's ABUS Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings increased its Arbutus Biopharma (ABUS) stake by 8.1% in Q2 2026, buying an estimated $28.4K and bringing the position to 85,939 shares worth $411K. The position accounts for ﹤0.01% of the portfolio, ranked #2101.

Mirae Asset Global ETFs Holdings first reported a position in ABUS in Q2 2024 and has held it in 9 quarters since. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Mirae Asset Global ETFs Holdings held 85,939 shares of Arbutus Biopharma worth $411K as of Q2 2026.
  • Mirae Asset Global ETFs Holdings bought 6,473 Arbutus Biopharma shares in Q2 2026, an estimated $28.4K.
  • Arbutus Biopharma made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #2101 holding.
  • Mirae Asset Global ETFs Holdings first reported a position in Arbutus Biopharma in Q2 2024 and has held it in 9 quarters since.
  • 176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.